MARKET

ACRS

ACRS

Aclaris Therapeutics Inc
NASDAQ
1.350
+0.030
+2.27%
After Hours: 1.310 -0.04 -2.96% 19:24 07/15 EDT
OPEN
1.330
PREV CLOSE
1.320
HIGH
1.370
LOW
1.300
VOLUME
608.95K
TURNOVER
0
52 WEEK HIGH
11.12
52 WEEK LOW
0.5902
MARKET CAP
96.21M
P/E (TTM)
-1.2372
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACRS last week (0708-0712)?
Weekly Report · 15h ago
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
NASDAQ · 6d ago
Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern about the company's prospects. Aclaris Therapeutics, Inc. And RENN Fund, Inc have recent notable insider transactions for penny stocks. The Dow Jones index closed higher by around 0.2% on Friday.
Benzinga · 07/08 13:01
Weekly Report: what happened at ACRS last week (0701-0705)?
Weekly Report · 07/08 09:11
Tuesday 7/2 Insider Buying Report: ACRS, KRON
NASDAQ · 07/02 14:41
Weekly Report: what happened at ACRS last week (0624-0628)?
Weekly Report · 07/01 09:11
Weekly Report: what happened at ACRS last week (0617-0621)?
Weekly Report · 06/24 09:12
Weekly Report: what happened at ACRS last week (0610-0614)?
Weekly Report · 06/17 09:11
More
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.

Webull offers Aclaris Therapeutics Inc stock information, including NASDAQ: ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.